<p>根據 Nuveen LLC 最近向 SEC 提交的 13F 表格，該公司在第一季度收購了 Aerovate Therapeutics, Inc.（NASDAQ:AVTE - 免費報告）的新頭寸。這家機構投資者收購了 40,047 股該公司的股票，價值約為 101,000 美元。截至最近報告期末，Nuveen LLC 持有 Aerovate Therapeutics 約 0.14% 的股份。</p>
<p>其他機構投資者和對沖基金也增加或減少了在該公司的股份。Two Sigma Advisers LP 在第四季度將其在 Aerovate Therapeutics 的持股增加了 38.5%。Two Sigma Advisers LP 現在擁有 153,600 股該公司的股票，價值 407,000 美元，此前在上個季度又購買了 42,700 股。Northern Trust Corp 在第四季度將其在 Aerovate Therapeutics 的持股增加了 6.3%。Northern Trust Corp 現在擁有 106,692 股該公司的股票，價值 283,000 美元，此前在上個季度又購買了 6,296 股。BNP Paribas Financial Markets 在第四季度以約 145,000 美元的價格購買了 Aerovate Therapeutics 的新頭寸。Rhumbline Advisers 在第一季度將其在 Aerovate Therapeutics 的持股增加了 67.3%。Rhumbline Advisers 現在擁有 22,750 股該公司的股票，價值 57,000 美元，此前在此期間又購買了 9,154 股。最後，Squarepoint Ops LLC 在第四季度以約 52,000 美元的價格收購了 Aerovate Therapeutics 的新股份。</p>
<p>獲取 <strong>Aerovate Therapeutics</strong> 的提醒：</p>
<h2>Aerovate Therapeutics 價格表現</h2>
<p>AVTE 週一開盤價為 7.77 美元。該公司的市值為 2.2521 億美元，市盈率為-2.60，貝塔值為 0.95。Aerovate Therapeutics, Inc.的 1 年最低價為 56.35 美元，1 年最高價為 105.00 美元。該公司的 50 日移動平均價格為 8.43 美元，200 日移動平均價格為 35.97 美元。</p>
<h2>Aerovate Therapeutics 簡介</h2>
<p>（免費報告）</p>
<p>Aerovate Therapeutics, Inc.是一家臨牀階段的生物製藥公司，開發能夠改善美國罕見心肺疾病患者生活的藥物。它專注於推進 AV-101，這是一種用於治療肺動脈高壓的乾粉吸入劑，目前處於 2b/3 期臨牀試驗中。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Aerovate Therapeutics</li>
<li>市值計算器：如何計算市值</li>
<li>聯合太平洋：為美國工業復興鋪軌</li>
<li>百分比漲幅告訴投資者什麼，以及為什麼它們並未告訴全部故事</li>
<li>TransDigm 的優勢：從備件到高額利潤</li>
<li>REIT 股票 - 今天添加到您投資組合中的最佳 REIT 股票</li>
<li>Spire Global：微型衞星、大量買入評級和上漲空間</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZURQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZURQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>您現在應該投資 1,000 美元在 Aerovate Therapeutics 嗎？</h2>
<p>在您考慮 Aerovate Therapeutics 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Aerovate Therapeutics 並不在名單上。</p>
<p>雖然 Aerovate Therapeutics 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

AVTE

<p>Nuveen LLC 已收購 Aerovate Therapeutics, Inc.（納斯達克代碼：AVTE）40,047 股，價值約 101,000 美元，佔該公司約 0.14% 的股份。其他機構投資者也調整了他們的持股比例，其中 Two Sigma Advisers LP 增加了 38.5% 的持股。Aerovate Therapeutics 是一家臨牀階段的生物製藥公司，專注於開發稀有心肺疾病的治療方案。該股票開盤價為 7.77 美元，市值為 2.2521 億美元，市盈率為 -2.60</p>

<p>Nuveen LLC acquired a new position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 40,047 shares of the company's stock, valued at approximately $101,000. Nuveen LLC owned approximately 0.14% of Aerovate Therapeutics at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>根據 Nuveen LLC 最近向 SEC 提交的 13F 表格，該公司在第一季度收購了 Aerovate Therapeutics, Inc.（NASDAQ:AVTE - 免費報告）的新頭寸。這家機構投資者收購了 40,047 股該公司的股票，價值約為 101,000 美元。截至最近報告期末，Nuveen LLC 持有 Aerovate Therapeutics 約 0.14% 的股份。</p>
</div><p>Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Two Sigma Advisers LP grew its holdings in Aerovate Therapeutics by 38.5% in the 4th quarter. Two Sigma Advisers LP now owns 153,600 shares of the company's stock worth $407,000 after buying an additional 42,700 shares in the last quarter. Northern Trust Corp grew its holdings in Aerovate Therapeutics by 6.3% in the 4th quarter. Northern Trust Corp now owns 106,692 shares of the company's stock worth $283,000 after buying an additional 6,296 shares in the last quarter. BNP Paribas Financial Markets bought a new position in Aerovate Therapeutics in the 4th quarter worth approximately $145,000. Rhumbline Advisers lifted its position in Aerovate Therapeutics by 67.3% in the first quarter. Rhumbline Advisers now owns 22,750 shares of the company's stock worth $57,000 after purchasing an additional 9,154 shares during the period. Finally, Squarepoint Ops LLC acquired a new stake in Aerovate Therapeutics in the fourth quarter worth approximately $52,000.</p>
<div class="lb-trans"><p>其他機構投資者和對沖基金也增加或減少了在該公司的股份。Two Sigma Advisers LP 在第四季度將其在 Aerovate Therapeutics 的持股增加了 38.5%。Two Sigma Advisers LP 現在擁有 153,600 股該公司的股票，價值 407,000 美元，此前在上個季度又購買了 42,700 股。Northern Trust Corp 在第四季度將其在 Aerovate Therapeutics 的持股增加了 6.3%。Northern Trust Corp 現在擁有 106,692 股該公司的股票，價值 283,000 美元，此前在上個季度又購買了 6,296 股。BNP Paribas Financial Markets 在第四季度以約 145,000 美元的價格購買了 Aerovate Therapeutics 的新頭寸。Rhumbline Advisers 在第一季度將其在 Aerovate Therapeutics 的持股增加了 67.3%。Rhumbline Advisers 現在擁有 22,750 股該公司的股票，價值 57,000 美元，此前在此期間又購買了 9,154 股。最後，Squarepoint Ops LLC 在第四季度以約 52,000 美元的價格收購了 Aerovate Therapeutics 的新股份。</p>
</div><p>Get <strong>Aerovate Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Aerovate Therapeutics</strong> 的提醒：</p>
</div><h2>Aerovate Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Aerovate Therapeutics 價格表現</h2>
</div><p>AVTE opened at $7.77 on Monday. The company has a market capitalization of $225.21 million, a price-to-earnings ratio of -2.60 and a beta of 0.95. Aerovate Therapeutics, Inc. has a 1-year low of $56.35 and a 1-year high of $105.00. The business has a 50 day moving average price of $8.43 and a two-hundred day moving average price of $35.97.</p>
<div class="lb-trans"><p>AVTE 週一開盤價為 7.77 美元。該公司的市值為 2.2521 億美元，市盈率為-2.60，貝塔值為 0.95。Aerovate Therapeutics, Inc.的 1 年最低價為 56.35 美元，1 年最高價為 105.00 美元。該公司的 50 日移動平均價格為 8.43 美元，200 日移動平均價格為 35.97 美元。</p>
</div><h2>Aerovate Therapeutics Profile</h2>
<div class="lb-trans"><h2>Aerovate Therapeutics 簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.</p>
<div class="lb-trans"><p>Aerovate Therapeutics, Inc.是一家臨牀階段的生物製藥公司，開發能夠改善美國罕見心肺疾病患者生活的藥物。它專注於推進 AV-101，這是一種用於治療肺動脈高壓的乾粉吸入劑，目前處於 2b/3 期臨牀試驗中。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Aerovate Therapeutics</li>
<li>Market Cap Calculator: How to Calculate Market Cap</li>
<li>Union Pacific: Laying the Tracks for America's Industrial Renewal</li>
<li>What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story</li>
<li>TransDigm’s Edge: From Spare Parts to Sky-High Profits</li>
<li>REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today</li>
<li>Spire Global: Tiny Satellites, Big Buy Ratings and Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Aerovate Therapeutics</li>
<li>市值計算器：如何計算市值</li>
<li>聯合太平洋：為美國工業復興鋪軌</li>
<li>百分比漲幅告訴投資者什麼，以及為什麼它們並未告訴全部故事</li>
<li>TransDigm 的優勢：從備件到高額利潤</li>
<li>REIT 股票 - 今天添加到您投資組合中的最佳 REIT 股票</li>
<li>Spire Global：微型衞星、大量買入評級和上漲空間</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZURQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AVTE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Aerovate Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元在 Aerovate Therapeutics 嗎？</h2>
</div><p>Before you consider Aerovate Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 Aerovate Therapeutics 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Aerovate Therapeutics 並不在名單上。</p>
</div><p>While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Aerovate Therapeutics 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Nuveen LLC 已收購了 Aerovate Therapeutics, Inc. $AVTE 的 40,047 股股票